Latest News

• 
  Male & Female Health

  New research finds air pollution reduces sperm counts through brain inflammation

  Written by Charlie King | 1 Nov 2021

  Researchers have long known that air pollution can increase the risk of disorders such as obesity, diabetes, and fertility, but they did not know the exact mechanism for… read more.

• 
  COVID-19

  Moderna announces positive top line data from phase II/III study of COVID-19 vaccine in children 6 to 11

  Written by Charlie King | 31 Oct 2021

  -Moderna Inc. announced positive interim data from the Phase II/III study, called the KidCOVE study, of mRNA-1273 , the Company’s vaccine candidate against COVID-19, in children 6 to… read more.

• 
  Diabetes & Endocrinology

  Whole grains could significantly reduce the economic impact of type 2 diabetes

  Written by Charlie King | 31 Oct 2021

  Increased consumption of whole grain foods could significantly reduce the incidence of type 2 diabetes and the costs associated with its treatment in Finland, according to a recent… read more.

• 
  Osteoporosis

  Phase III ATOM trial of Tymlos shows positive results in osteoporosis – Radius Health

  Written by Charlie King | 30 Oct 2021

  Radius Health announced positive topline results from the ATOM study evaluating Tymlos (abaloparatide) 80mcg subcutaneous (SC) for use in males with osteoporosis. The ATOM study met its primary… read more.

• 
  ENT

  Sense of smell is our most rapid warning system

  Written by Charlie King | 30 Oct 2021

  The ability to detect and react to the smell of a potential threat is a precondition of our and other mammals’ survival. Using a novel technique, researchers at… read more.

• 
  Haematology

  NICE (UK) recommends Adakveo as a treatment for preventing recurrent sickle cell crises – Novartis

  Written by Charlie King | 29 Oct 2021

  Novartis is pleased to announce that eligible patients in England and Wales will soon have routine access to Adakveo (crizanlizumab) under a Managed Access Agreement (MAA). The news… read more.

• 
  Gastroenterology

  Antibiotics for appendicitis – first-line treatment

  Written by Charlie King | 29 Oct 2021

  Antibiotics are now an accepted first-line treatment for most people with appendicitis, according to final results of the Comparing Outcomes of antibiotic Drugs and Appendectomy (CODA) trial, and… read more.

• 
  Mental Health

  Mirtazapine is ineffective, possibly dangerous, for agitation in dementia

  Written by Bruce Sylvester | 28 Oct 2021

  Mirtazapine, an antidepressant often used to treat agitation in patients with dementia, is ineffective, researchers reported on Oct. 21, 2021 in The Lancet. And the investigators found a… read more.

• 
  Diabetes & Endocrinology

  Oral contraceptive reduces risk of diabetes in women with polycystic ovary syndrome

  Written by Bruce Sylvester | 28 Oct 2021

  Use of combined oral contraceptives appears to significantly reduce the risk of type 2 diabetes in women with polycystic ovary syndrome (PCOS). Researchers reported this finding on Oct…. read more.

• 
  COVID-19

  FDA Advisory Committee unanimously votes in support of emergency use for a booster dose of Moderna’s COVID-19 Vaccine in the U.S

  Written by Charlie King | 27 Oct 2021

  Moderna, Inc. confirmed that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended that the FDA grant an Emergency Use Authorization (EUA) for a booster dose… read more.

• 
  Immunology

  New EULAR consensus on prevention trials in people at risk of developing RA

  Written by Charlie King | 27 Oct 2021

  RA is an inflammatory autoimmune disease that causes pain, swelling and stiffness in the joints. It can also cause fatigue, and the underlying inflammation may affect other body… read more.

• 
  Immunology

  FDA approves expanded indication of Biktarvy for treatment of HIV-1 in pediatric populations – Gilead Sciences

  Written by Charlie King | 26 Oct 2021

  Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing… read more.